Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT05490901
Recruiting Observational

The Prognostic Role and Diagnostic Efficacy of Exercise Right Heart Catheterization With a Simultaneous Echocardiography in Patients With Dyspnea on Exertion

NCT05490901 · tracked via the Priya Life Science South Korea tracker
Sponsor
Samsung Medical Center
Phase
Observational
Started
2020-03-17
Last updated
2022-08-08

Condition(s) studied

Heart Failure With Preserved Ejection FractionChronic Pulmonary Thromboembolism (Disorder)

Investigational drug(s) / intervention(s)

Exercise hemodynamic test

Exercise hemodynamic test: Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography

Study summary

To evaluate the role of exercise hemodynamic testing in the diagnostic workup for patients with dyspnea on exertion referred to the catheterization lab.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject must be at least 19 years of age. * Patients with dyspnea on exertion * Written informed consent of participating subjects after being fully briefed (for prospective analysis) Exclusion Criteria: * Patients with incomplete hemodynamic data at rest or exercise * Advanced tumor disease or other diseases with a short life expectancy * Uncontrolled systemic arterial hypertension ( \> 160/100 mmHg at rest) * FEV1\<50% predicted * TLC\<60% predicted

Primary outcome measure(s)

  • Proportion of exercise induced pulmonary artery wedge pressure >25 mmHg — during the procedure
    Number of Participants with Diagnosis of earlier heart failure with preserved ejection fraction based on exercise PCWP

Trial sites (1)

FacilityCityRegionStatus
Samsung Medical Center Seoul South Korea Recruiting

More Samsung Medical Center trials in South Korea

IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute MI Recruiting
Genomic Profiling of Pancreatic Cystic Tumors Starting soon
Head and Neck Cancer Omics/Integrated Precision Medicine (HOPE) Recruiting
Korean Stroke Cohort for Functioning and Rehabilitation-II Active, not recruiting
Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer Recruiting

Other trials for the same condition

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity Recruiting
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05490901 on ClinicalTrials.gov ↗ ← All trials in South Korea